elliot  Servais  to  Lung Neoplasms
                            
                            
                                This is a "connection" page, showing publications  elliot  Servais  has written about  Lung Neoplasms.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            4.687
         
        
        
     
 
    
        
        - 
            Watkins AA, Rizvi TZ, Lopez E, Shehata D, Ssemaganda H, Lin Z, Stock CT, Moffatt-Bruce SD, Servais EL. Trends and comparative outcomes between operative approaches for segmentectomy in lung cancer. J Thorac Cardiovasc Surg. 2025 Mar; 169(3):745-752.e2.
            
            
                Score: 0.564
             
- 
            Servais EL. Commentary: Utilization and equity in lung cancer screening: Time to abandon the 1-size-fits-all approach? J Thorac Cardiovasc Surg. 2024 Jul; 168(1):261-262.
            
            
                Score: 0.541
             
- 
            Kader S, Watkins A, Servais EL. The oncologic efficacy of extended thoracic resections. J Surg Oncol. 2023 Feb; 127(2):288-295.
            
            
                Score: 0.510
             
- 
            Servais EL, Miller DL, Thibault D, Hartwig MG, Kosinski AS, Stock CT, Price T, Quadri SM, D'Agostino RS, Burfeind WR. Conversion to Thoracotomy During Thoracoscopic vs Robotic Lobectomy: Predictors and Outcomes. Ann Thorac Surg. 2022 08; 114(2):409-417.
            
            
                Score: 0.472
             
- 
            Su L, Ho H, Stock CT, Quadri SM, Williamson C, Servais EL. Surgeon Experience Is Associated With Prolonged Air Leak After Robotic-assisted Pulmonary Lobectomy. Ann Thorac Surg. 2022 08; 114(2):434-441.
            
            
                Score: 0.461
             
- 
            Watkins AA, Quadri SM, Servais EL. Robotic-Assisted Complex Pulmonary Resection: Sleeve Lobectomy for Cancer. Innovations (Phila). 2021 Mar-Apr; 16(2):132-135.
            
            
                Score: 0.447
             
- 
            Ho H, Williamson C, Regis SM, Stock CT, Quadri SM, McKee BJ, McKee AB, Servais EL. Surgery and invasive diagnostic procedures for benign disease are rare in a large low-dose computed tomography lung cancer screening program. J Thorac Cardiovasc Surg. 2021 Mar; 161(3):790-802.e2.
            
            
                Score: 0.432
             
- 
            Servais E, Swanson SJ. Thoracoscopic Management of Pulmonary Metastases. Thorac Surg Clin. 2016 Feb; 26(1):91-7.
            
            
                Score: 0.314
             
- 
            Servais EL, Colovos C, Kachala SS, Adusumilli PS. Pre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden. Curr Protoc Pharmacol. 2011 Sep; Chapter 14:Unit14.21.
            
            
                Score: 0.231
             
- 
            Suaiti L, Sullivan TB, Rieger-Christ KM, Servais EL, Suzuki K, Burks EJ. Vascular Invasion Predicts Recurrence in Stage IA2-IB Lung Adenocarcinoma but not Squamous Cell Carcinoma. Clin Lung Cancer. 2023 05; 24(3):e126-e133.
            
            
                Score: 0.127
             
- 
            Yambayev I, Sullivan TB, Rieger-Christ KM, Servais EL, Stock CT, Quadri SM, Sands JM, Suzuki K, Burks EJ. Vascular invasion identifies the most aggressive histologic subset of stage I lung adenocarcinoma: Implications for adjuvant therapy. Lung Cancer. 2022 09; 171:82-89.
            
            
                Score: 0.123
             
- 
            Towe CW, Servais EL, Grau-Sepulveda M, Kosinski AS, Brown LM, Broderick SM, Wormuth DW, Fernandez FG, Kozower BD, Raymond DP. Impact of Chest Wall Resection on Mortality After Lung Resection for Non-Small Cell Lung?Cancer. Ann Thorac Surg. 2022 12; 114(6):2023-2031.
            
            
                Score: 0.118
             
- 
            Yambayev I, Sullivan TB, Suzuki K, Zhao Q, Higgins SE, Yilmaz OH, Litle VR, Moreira P, Servais EL, Stock CT, Quadri SM, Williamson C, Rieger-Christ KM, Burks EJ. Pulmonary Adenocarcinomas of Low Malignant Potential: Proposed Criteria to Expand the Spectrum Beyond Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. Am J Surg Pathol. 2021 04 01; 45(4):567-576.
            
            
                Score: 0.112
             
- 
            Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014 Nov 05; 6(261):261ra151.
            
            
                Score: 0.072
             
- 
            Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, Chou J, Sima CS, Vertes E, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res. 2014 Feb 15; 20(4):1020-8.
            
            
                Score: 0.068
             
- 
            Stiles BM, Servais EL, Lee PC, Port JL, Paul S, Altorki NK. Point: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. J Thorac Cardiovasc Surg. 2009 Jan; 137(1):13-9.
            
            
                Score: 0.048
             
- 
            Kachala SS, Servais EL, Park BJ, Rusch VW, Adusumilli PS. Therapeutic sentinel lymph node imaging. Semin Thorac Cardiovasc Surg. 2009; 21(4):327-38.
            
            
                Score: 0.048